**AMENDMENTS TO THE CLAIMS** 

1-8. (Canceled)

9. (Currently amended) A [[host]] zebrafish cell transformed with a reporter nucleic

acid comprising a [[first]] DNA segment consisting of nucleotides 3005-4336 of SEQ ID NO:1

contiguous to nucleotides 1-243 of SEQ ID NO:1, or a second DNA segment which is at least

80% identical to said first DNA segment across nucleotides 3005-3484 of SEQ-ID-NO:1 and

having the same reporter and mRNA terminator function as said first DNA segment.

10. (Currently amended) The host cell of Claim 9 which is a A zebrafish cell

comprising a reporter nucleic acid comprising a DNA segment which is at least 98% identical to

and having the same reporter function as nucleotides 3005-4336 of SEQ ID NO:1 contiguous to

nucleotides 1-243 of SEQ ID NO:1.

11. (Currently amended) A transgenic zebrafish comprising a reporter nucleic acid

comprising a [[first]] DNA segment consisting of nucleotides 3005-4336 of SEQ ID NO:1

contiguous to nucleotides 1-243 of SEQ ID NO:1, or a second DNA segment which is at least

80% identical to said first DNA segment across nucleotides 3005-3484 of SEO ID NO:1 and

having the same reporter and mRNA terminator function as said first DNA segment.

12. (Original) The transgenic zebrafish of Claim 11 which further comprises an

induced mutation.

13. (Previously presented) The transgenic zebrafish of Claim 12, wherein the

mutation has been induced by chemical mutagenesis.

LAW OFFICES OF CHRISTENSEN O'CONNOR JOHNSON KINDNESSPLLC 1420 Fifth Avenue

1420 Fifth Avenue Suite 2800

Seattle, Washington 98101 206.682.8100

14. (Previously presented) The transgenic zebrafish of Claim 12, wherein the

mutation has been induced by insertional retrovirus mutagenesis.

15. (Withdrawn) A method for identifying a gene that modulates the \( \beta \)-catenin

signaling pathway which comprises:

analyzing the level of expression of the reporter nucleic acid contained in a transgenic

zebrafish of Claim 11 which also comprises an induced mutation;

analyzing the level of expression of said reporter nucleic acid contained in a control

transgenic zebrafish without said mutation;

comparing the levels of expression of said reporter nucleic acid to identify zebrafish with

said mutation having an altered level of expression of said reporter nucleic acid; and

identifying the gene containing the induced mutation.

16. (Withdrawn) A method for identifying a gene that modulates the β-catenin

signaling pathway which comprises:

analyzing the level of expression of the reporter nucleic acid contained in a transgenic

zebrafish of Claim 30 which also comprises an induced mutation;

analyzing the level of expression of said reporter nucleic acid contained in a control

transgenic zebrafish without said mutation;

comparing the levels of expression of said reporter nucleic acid to identify zebrafish with

said mutation having an altered level of expression of said reporter nucleic acid; and

identifying the gene containing the induced mutation.

17. (Withdrawn) A method for identifying a gene that modulates the β-catenin

signaling pathway which comprises:

analyzing the level of expression of the reporter nucleic acid contained in a transgenic

-3-

zebrafish of Claim 32 which also comprises an induced mutation;

LAW OFFICES OF CHRISTENSEN O'CONNOR JOHNSON KINDNESS<sup>PLIC</sup> 1420 Fifth Avenue

206.682.8100

analyzing the level of expression of said reporter nucleic acid contained in a control

transgenic zebrafish without said mutation;

comparing the levels of expression of said reporter nucleic acid to identify zebrafish with

said mutation having an altered level of expression of said reporter nucleic acid; and

identifying the gene containing the induced mutation.

18. (Withdrawn) A method for identifying a gene that modulates the \( \beta \)-catenin

signaling pathway which comprises:

analyzing the level of expression of the reporter nucleic acid of Claim 7 contained in a

transgenic zebrafish which also comprises an induced mutation;

analyzing the level of expression of said reporter nucleic acid contained in a control

transgenic zebrafish without said mutation;

comparing the levels of expression of said reporter nucleic acid to identify zebrafish with

said mutation having an altered level of expression of said reporter nucleic acid; and

identifying the gene containing the induced mutation.

19. (Withdrawn) A method for identifying a gene that modulates the β-catenin

signaling pathway which comprises:

analyzing the level of expression of the reporter nucleic acid of Claim 8 contained in a

transgenic zebrafish which also comprises an induced mutation;

analyzing the level of expression of said reporter nucleic acid contained in a control

transgenic zebrafish without said mutation;

comparing the levels of expression of said reporter nucleic acid to identify zebrafish with

-4-

said mutation having an altered level of expression of said reporter nucleic acid; and

identifying the gene containing the induced mutation.

LAW OFFICES OF CHRISTENSEN O'CONNOR JOHNSON KINDNESS\*\*LLC 1420 Fifth Avenue

Suite 2800

Seattle, Washington 98101 206.682.8100 20. (Withdrawn) The method of Claim 15, wherein the altered level of expression is

a reduction or loss of expression.

21. (Withdrawn) The method of Claim 15, wherein the altered level of expression is

an increase.

22. (Withdrawn) A method for screening a candidate drug that is potentially useful

for the treatment or prevention of a disease condition involving a β-catenin signaling pathway

which comprises:

analyzing the level of expression of the reporter nucleic acid contained in a transgenic

zebrafish of Claim 11 in the presence of a candidate drug;

analyzing the level of expression of said reporter nucleic acid contained in said transgenic

zebrafish in the absence of the candidate drug;

comparing the levels of expression of said reporter nucleic acid to identify an altered

level of expression of said reporter nucleic acid in the presence of said candidate drug, wherein

an altered level of expression of said reporter nucleic acid is indicative of a drug useful for the

treatment or prevention of said disease condition.

23. (Withdrawn) A method for screening a candidate drug that is potentially useful

for the treatment or prevention of a disease condition involving a β-catenin signaling pathway

which comprises:

analyzing the level of expression of the reporter nucleic acid contained in a transgenic

zebrafish of Claim 30 in the presence of a candidate drug;

analyzing the level of expression of said reporter nucleic acid contained in said transgenic

-5-

zebrafish in the absence of the candidate drug:

LAW OFFICES OF CHRISTENSEN O'CONNOR JOHNSON KINDNESSPLLC 1420 Fifth Avenue

comparing the levels of expression of said reporter nucleic acid to identify an altered

level of expression of said reporter nucleic acid in the presence of said candidate drug, wherein

an altered level of expression of said reporter nucleic acid is indicative of a drug useful for the

treatment or prevention of said disease condition.

24. (Withdrawn) A method for screening a candidate drug that is potentially useful

for the treatment or prevention of a disease condition involving a B-catenin signaling pathway

which comprises:

analyzing the level of expression of the reporter nucleic acid contained in a transgenic

zebrafish of Claim 32 in the presence of a candidate drug;

analyzing the level of expression of said reporter nucleic acid contained in said transgenic

zebrafish in the absence of the candidate drug;

comparing the levels of expression of said reporter nucleic acid to identify an altered

level of expression of said reporter nucleic acid in the presence of said candidate drug, wherein

an altered level of expression of said reporter nucleic acid is indicative of a drug useful for the

treatment or prevention of said disease condition.

25. (Withdrawn) A method for screening a candidate drug that is potentially useful

for the treatment or prevention of a disease condition involving a β-catenin signaling pathway

which comprises:

analyzing the level of expression of the reporter nucleic acid of Claim 7 contained in a

transgenic zebrafish in the presence of a candidate drug;

analyzing the level of expression of said reporter nucleic acid contained in said transgenic

zebrafish in the absence of the candidate drug;

LAW OFFICES OF CHRISTENSEN O'CONNOR JOHNSON KINDNESSPLLC 1420 Fifth Avenue

Suite 2800 Seattle, Washington 98101 206.682.8100

-6-

comparing the levels of expression of said reporter nucleic acid to identify an altered

level of expression of said reporter nucleic acid in the presence of said candidate drug, wherein

an altered level of expression of said reporter nucleic acid is indicative of a drug useful for the

treatment or prevention of said disease condition.

26. (Withdrawn) A method for screening a candidate drug that is potentially useful

for the treatment or prevention of a disease condition involving a \( \mathcal{B} \)-catenin signaling pathway

which comprises:

analyzing the level of expression of the reporter nucleic acid of Claim 8 contained in a

transgenic zebrafish in the presence of a candidate drug;

analyzing the level of expression of said reporter nucleic acid contained in said transgenic

zebrafish in the absence of the candidate drug;

comparing the levels of expression of said reporter nucleic acid to identify an altered

level of expression of said reporter nucleic acid in the presence of said candidate drug, wherein

an altered level of expression of said reporter nucleic acid is indicative of a drug useful for the

treatment or prevention of said disease condition.

27. (Withdrawn) The method of Claim 22, wherein the altered level of expression is

a reduction or loss of expression.

28. (Withdrawn) The method of Claim 22, wherein the altered level of expression is

an increase.

29. (Withdrawn) The method of Claim 22, wherein said disease condition is

-7-

melanoma, colorectal cancer or osteoporosis.

30. (Canceled)

> LAW OFFICES OF CHRISTENSEN O'CONNOR JOHNSON KINDNESSPILE 1420 Fifth Avenue

Suite 2800

Scattle, Washington 98101 206.682.8100

- 31. (Currently amended) [[The]] A transgenic zebrafish comprising a reporter nucleic acid comprising a DNA segment which is at least 98% identical to and having the same reporter function as nucleotides 3005-4336 of SEQ ID NO:1 contiguous to nucleotides 1-243 of SEQ ID NO:1 of Claim-11 wherein the reporter nucleic acid comprises said second DNA segment.
- 32. (Previously presented) The transgenic zebrafish of Claim 31 wherein a nucleic acid sequence encoding a wild-type GFP or a sequence having at least 98% identity to said wild-type GFP replaces nucleotides 3485-4330 of SEQ ID NO:1.
- 33. (Previously presented) The transgenic zebrafish of Claim 31 wherein the nucleic acid encoding a wild-type GFP consists of the nucleotide sequence set forth in SEQ ID NO:2.

206.682.8100